Immunocore (NASDAQ:IMCR) Releases Earnings Results, Misses Expectations By $0.15 EPS

Immunocore (NASDAQ:IMCR) announced its earnings results on Friday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.15), FiscalAI reports. Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%.

Immunocore Trading Up 9.1%

IMCR stock traded up $2.59 during trading on Friday, reaching $30.99. 1,526,513 shares of the stock were exchanged, compared to its average volume of 507,836. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -83.75 and a beta of 0.82. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 1 year low of $27.50 and a 1 year high of $40.71. The business has a 50 day moving average price of $31.64 and a 200-day moving average price of $31.73.

Analysts Set New Price Targets

A number of brokerages have commented on IMCR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. TD Cowen raised Immunocore to a “strong-buy” rating in a report on Monday, August 24th. JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a report on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price on the stock. Mizuho lifted their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $55.86.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.